Vivo Capital bags $635M for its new biotech public company fund
Vivo Capital has raised a whopping $635 million for a new biotech public company fund — pretty much perfect timing for an investment group with deep roots in the transpacific region and a big interest in IPOs and both small and mid-sized public companies.
The Vivo Opportunity Fund was oversubscribed, which may not come as too much of a surprise. The group has offices in Palo Alto, Beijing, Shanghai and Taipei and a track record that includes a long list of private and public biotech financings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.